|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 26, 2017 ) Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)-Integrin beta-3 (β3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin fibronectin laminin matrix metalloproteinase-2 osteopontin osteomodulin prothrombin thrombospondin vitronectin and von Willebrand factor. Activation of integrin alpha-IIb/beta-3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) pipeline Target constitutes close to 20 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II IND/CTA Filed Preclinical and Discovery stages are 3 1 8 and 1 respectively. Similarly the universities portfolio in Preclinical stages comprises 7 molecules respectively. Report covers products from therapy areas Oncology Metabolic Disorders Ophthalmology Cardiovascular Dermatology Gastrointestinal and Infectious Disease which include indications Wet (Neovascular / Exudative) Macular Degeneration Glioblastoma Multiforme (GBM) Breast Cancer Diabetic Retinopathy Melanoma Arterial Thrombosis Cardiovascular Disease Diabetic Macular Edema Diabetic Nephropathy Ischemic Cerebral Stroke Lung Cancer Malabsorption Syndrome Metastatic Melanoma Multiple Myeloma (Kahler Disease) Myocardial Infarction Pancreatic Cancer Sepsis and Venous Leg Ulcers (Crural ulcer) .
The latest report Integrin Beta 3-Pipeline Review H2 2017 outlays comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more information about this report at http://www.reportsweb.com/integrin-beta-3-pipeline-review-h2-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
- The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881478/sample
Reasons to buy
- Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Factor Therapeutics Ltd
Merck & Co Inc
SciFluor Life Sciences LLC
SOM Biotech SL
Vascular Pharmaceuticals Inc
VDDI Pharmaceuticals
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881478/discount
List of Tables
Number of Products under Development by Stage of Development H2 2017
Number of Products under Development by Therapy Areas H2 2017
Number of Products under Development by Indication H2 2017
Number of Products under Development by Companies H2 2017
Products under Development by Companies H2 2017
Number of Products under Investigation by Universities/Institutes H2 2017
Products under Investigation by Universities/Institutes H2 2017
Number of Products by Stage and Mechanism of Actions H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Pipeline by Factor Therapeutics Ltd H2 2017
Pipeline by Merck & Co Inc H2 2017
Pipeline by SciFluor Life Sciences LLC H2 2017
Pipeline by SOM Biotech SL H2 2017
Pipeline by Vascular Pharmaceuticals Inc H2 2017
Pipeline by VDDI Pharmaceuticals H2 2017
Dormant Products H2 2017
Dormant Products H2 2017 (Contd..1) H2 2017
Dormant Products H2 2017 (Contd..2) H2 2017
Discontinued Products H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881478/buy/3500
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
